Taken together, the PDLIM7/PDLIM2/p62-mediated degradation pathway to terminate p65 activation may prevent the onset of these autoimmune diseases and could be a novel molecular target for the treatment of autoimmune diseases. Here, PDLIM2 is linked to autoimmune disease.